Sprint Bioscience Employee Directory
Pharmaceutical ManufacturingStockholm, Sweden11-50 Employees
Sprint Bioscience is a Swedish company focused on early-stage drug development in cancer. Based in Huddinge in the Stockholm region, Sweden, it develops novel drug candidates in the initial stages of the pipeline for oncology indications. The firm is a small to midsize organization pursuing cancer-focused programs at the earliest development stage. In 2025, the company sold one of its cancer programs, TREX1, to Gilead Sciences. It has pursued collaborations to broaden its pipeline, including a 2025 agreement with the Experimental Drug Development Centre in Singapore to extend its MASH program into inflammatory diseases. Earlier, in 2024, Sprint Bioscience announced a drug development program for acute myeloid leukemia, and in 2023 entered into a licensing and research collaboration with Day One Biopharmaceuticals for its VRK1 program.